



-

PRESS RELEASE

Subject: Investment in Peripherex Inc.

BiLight is proud to announce that on July 27 2021, it signed an investment agreement with Peripherex Inc., a private American company that develops solutions for diagnostic and monitoring of peripheral vision impairment using a personal computer and a built-in camera by monitoring eye movements. The test is designed to check for suspicion or the development of glaucoma and other eye diseases that affect peripheral vision ("Peripherex Product").

Peripherex was founded on the basis of an invention of Professor Jeffrey Goldberg, who serves as Chair of Ophthalmology at the Byers Eye Institute at Stanford University and in collaboration with the Israeli company UMOOVE.

According to the agreement terms, the Company shall invest a total of up to \$1 million USD ("Investment Amount"), in consideration for Preferred A shares and the right to appoint a director. \$500,000 USD of the Investment Amount was invested upon signature and closing of the agreement ("Initial Closing") and the remaining \$500,000, at the discretion of the Company, upon Peripherex completing the development and installation of the Peripherex Product in the clinics of at least four major opinion key leaders (KOL's) specializing in glaucoma in the U.S. who will start using the Peripherex Product in their clinics.

In addition, the Company was also granted an option to invest up to an additional \$2 million until the later of receipt of FDA approval of the Peripherex Product or 18 months from the Initial Closing, at the same price per share stipulated in the agreement (the "Option").

Upon investing the Investment Amount, the Company is expected to hold approximately 25% of the share capital of Peripherex (on a fully diluted basis). Assuming full exercise of the Option, the Company is expected to hold approximately 50% of the share capital of Peripherex (on a fully diluted basis).

The Company's investment in Peripherex is part of BioLight aim to expand within the space of combinations of ophthalmology and Digital Health with preference to those companies that are relatively close to commercial launch of products.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye diseases and their treatment. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplifying the enormous potential of innovation in the ophthalmological technologies. The ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.